@article{ref1,
title="Antidepressant medications and osteoporosis",
journal="Bone",
year="2012",
author="Rizzoli, R. and Cooper, Colin and Reginster, J-y and Abrahamsen, Bo and Adachi, Jonathan D. and Brandi, Maria Luisa and Bruyère, O. and Compston, Juliet E. and Ducy, P. and Ferrari, S. and Harvey, N. C. and Kanis, J. A. and Karsenty, G. and Laslop, A. and Rabenda, V. and Vestergaard, P.",
volume="51",
number="3",
pages="606-613",
abstract="Use of antidepressant medications that act on the serotonin system has been linked to detrimental impacts on bone mineral density (BMD), and to osteoporosis. This article reviews current evidence for such effects, and identifies themes for future research. Serotonin receptors are found in all major types of bone cell (osteoblasts, osteocytes, and osteoclasts), indicating an important role of the neuroendocrine system in bone. Observational studies indicate a complex relationship between depression, antidepressants, and fracture. First, the presence of depression itself increases fracture risk, in relation with decreased BMD and an increase in falls. A range of aspects of depression may operate, including behavioral factors (e.g., smoking and nutrition), biological changes, and confounders (e.g., comorbidities and concomitant medications). A substantial proportion of depressed patients receive antidepressants, mostly selective serotonin reuptake inhibitors (SSRIs). Some of these have been linked to decreased BMD (SSRIs) and increased fracture risk (SSRIs and tricyclic agents). Current use of SSRIs and tricyclics increases fracture risk by as much as twofold versus nonusers, even after adjustment for potential confounders. While there is a dose-response relationship for SSRIs, the effect does not appear to be homogeneous across the whole class of drugs and may be linked to affinity for the serotonin transporter system. The increase in risk is greatest in the early stages of treatment, with a dramatic increase after initiation, reaching a peak within 1month for tricyclics and 8months for SSRIs. Treatment-associated increases in risk diminish towards baseline in the year following discontinuation. The body of evidence suggests that SSRIs should be considered in the list of medications that are risk factors for osteoporotic fractures.<p /> <p>Language: en</p>",
language="en",
issn="8756-3282",
doi="10.1016/j.bone.2012.05.018",
url="http://dx.doi.org/10.1016/j.bone.2012.05.018"
}